MRK Banks on Growing Pipeline & New Drugs to Offset Keytruda LOE
Merck is preparing for the 2028 loss of exclusivity for its blockbuster cancer drug Keytruda by significantly expanding its drug pipeline. The company's phase III pipeline has nearly tripled since 2021, with 20 new drugs expected by 2030 and over $70 billion in potential pipeline opportunity by the mid-2030s. Emerging growth drivers include Winrevair, Capvaxive, and Welireg, positioning Merck for continued growth despite Keytruda's anticipated sales decline once biosimilars enter the market.